Company / Cash & Equivalents
HARVARD BIOSCIENCE INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.6M
FY2025
5-year range
$4.1M / $8.6M
FY2021-FY2025
Trend
+109.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 4 years of decline, reaching $9M.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +0.7%.
Improved from $4M to $9M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +24.1%
- 5-Year CAGR
- +0.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 109.7% year-over-year.
- Peak cash & equivalents was recorded in FY2016.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.6M | +109.7% |
| FY2024 | $4.1M | -4.1% |
| FY2023 | $4.3M | -5.0% |
| FY2022 | $4.5M | -42.4% |
| FY2021 | $7.8M | -6.2% |
| FY2020 | $8.3M | +0.0% |
| FY2019 | $8.3M | +60.5% |
| FY2018 | $5.2M | -7.2% |
| FY2017 | $5.6M | -60.4% |
| FY2016 | $14.1M | -45.2% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026